LEADER 03139nam  2200361z- 450 
001 9910136403703321
005 20210211
035   $a(CKB)3710000000612060
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54550
035   $a(oapen)doab54550
035   $a(EXLCZ)993710000000612060
100   $a20202102d2014      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNew anti-infective strategies for treatment of tularemia
210   $cFrontiers Media SA$d2014
215   $a1 online resource (78 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88919-339-X 
330   $aFrancisella tularensis, the causative agent of tularemia, is a paradigm among human pathogens. This Gram-negative bacterium has an intracellular lifestyle, which probably reflects an adaptation to its natural animal and protozoa reservoirs. This is one of the most infectious agents in humans and animals; only a few bacteria are needed to induce a severe infection in both types of hosts. The clinical presentation and severity of human tularemia varies according to the portal of entry of bacteria, the bacterial inoculum, the virulence of the infecting strain, and the immune response of the host. Although most infections occur after direct inoculation of bacteria through the skin (through skin wounds or bites of arthropods), pneumonia due to inhalation of infected aerosols is the most feared of the clinical forms of the disease, particularly in the context of biological threat. Two subspecies are responsible for tularemia (subsp. tularensis and subsp. holarctica), and several clades have been described for each, which might be associated with changes in disease severity in humans. Tularemia is also more severe in people with an impaired immune response. No safe vaccine is currently available for prophylaxis of tularemia in humans. On the other hand, control of proliferation of F. tularensis in wildlife is not feasible. Thus, only the anti-infective agents are used for treatment and prophylaxis of human tularemia. The standard options include aminoglycosides (gentamicin), tetracyclines (eg, doxycycline) and fluoroquinolones (eg, ciprofloxacin). The selection of acquired resistance to these antibiotics in F. tularensis, especially in the context of a biological threat, may quickly limit the therapeutic options. New prophylactic and therapeutic alternatives must be developed rapidly. The present Research Topic focuses on potential new strategies for treatment of tularemia, including the development and evaluation of new compounds having proper antibacterial activity, reducing the virulence of F. tularensis or enhancing the immune host response.
610   $aantiinfective agents
610   $aFrancisella tularensis
610   $aimmunomodulators
610   $aTularemia
610   $aVirulence
700   $aMax Maurin$4auth$01287805
906   $aBOOK
912   $a9910136403703321
996   $aNew anti-infective strategies for treatment of tularemia$93020428
997   $aUNINA